Analyst Travis Steed of Bank of America Securities reiterated a Buy rating on Becton Dickinson (BDX – Research Report), boosting the price target to $269.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Travis Steed’s rating is based on Becton Dickinson’s strategic decision to separate its Biosciences and Diagnostic Solutions segments, potentially unlocking significant value for shareholders. The spin-off could result in a sum-of-the-parts valuation of $269 per share, suggesting substantial upside from the current price. Additionally, there is the potential for further value creation through a sale, as indicated by management.
The company has also demonstrated strong financial performance, with BDX’s first-quarter organic revenue growth exceeding expectations and an EPS beat, which contributes to a positive outlook. The management’s conservative guidance and improved execution further bolster confidence in the company’s prospects. With these factors in mind, Travis Steed reiterates a Buy rating, seeing continued value creation opportunities for BDX.
According to TipRanks, Steed is a 5-star analyst with an average return of 12.0% and a 70.10% success rate. Steed covers the Healthcare sector, focusing on stocks such as Medtronic, Becton Dickinson, and Boston Scientific.
In another report released on February 3, Wells Fargo also maintained a Buy rating on the stock with a $275.00 price target.